# PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

> **NCT00088231** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Agnogenic Myeloid Metaplasia
- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Imatinib Mesylate (Gleevec)
- **DRUG:** PTK 787 (vatalanib)

## Key facts

- **NCT ID:** NCT00088231
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2012-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088231, "PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00088231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*